Latest News

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 28x, you may consider Nava...

Burford Capital (NYSE:BUR) is expected to deliver standout growth this year, with revenue forecast to rise 17.6% annually and earnings projected to climb 28.1% each year, both well ahead of the broader US market averages. The company’s net profit margin has increased to 54.6% from last year’s 47.2%, supported by a strong five-year earnings growth rate of 37.7%. Trading at a Price-to-Earnings ratio of 8.6x, which is well below industry and peer averages, and currently priced at $9.47 versus an...

8x8 (EGHT) remains unprofitable, but over the past five years, the company has steadily reduced its losses by 34.4% per year. Its valuation stands out in the crowded software space, trading at a Price-To-Sales Ratio of just 0.4x. This figure is significantly below both the peer average of 15.9x and the US software industry average of 5.1x. While this low multiple may attract value-oriented investors, the share price has displayed notable volatility recently, and the lack of accelerating...

Fortrea Holdings (FTRE) remains unprofitable, with losses accelerating at a 52.8% annual rate over the past five years. Looking ahead, analysts expect the company to stay in the red for at least three more years, while revenue growth is projected at just 2.4% per year, lagging the US market’s 10.5%. Despite trading at a Price-to-Sales Ratio of 0.4x, which is well below industry and peer averages, the current share price of $11.95 sits significantly under the estimated fair value of $18.73...

Kornit Digital (NasdaqGS:KRNT) remains unprofitable this period, with losses having deepened at an average rate of 31.6% per year over the last five years. While revenue is projected to grow by 7.6% per year going forward, this pace lags behind the US market average of 10.5%, and profit margin has failed to show improvement. Shares are trading at $12.50, putting the Price-to-Sales multiple at 2.8x, which is well above peers and the broader machinery industry. Fair value is estimated at...

Atlanta Braves Holdings (BATR.K) remains unprofitable but has managed to reduce its losses by 6.9% per year over the past five years. With earnings projected to grow at 61.05% annually and the turning point to profitability anticipated within three years, ongoing loss reduction and expected profit growth are now the key points for investors keeping an eye on the company's earnings trajectory. See our full analysis for Atlanta Braves Holdings. Next up, we will stack these headline results...

Recursion Pharmaceuticals (RXRX) remains firmly in the red, with losses increasing at an average rate of 35.2% per year over the past five years and no improvement in net profit margin. Despite this, revenue is forecast to accelerate at an impressive 30.1% per year, outpacing the broader US market’s projected 10.5% annual growth. Investors are weighing strong top-line growth expectations against a persistent track record of operating losses, a premium price-to-sales ratio of 33.6x, and a...

Lemonade (LMND) is forecast to grow revenue at 27.1% per year, outpacing the US market average of 10.5% per year. Still, the company remains unprofitable, with losses increasing at a rate of 5.7% per year over the past five years and profitability not expected within the next three years. While investors may be drawn to the rapid growth potential, ongoing losses and lack of near-term profitability are likely to weigh on sentiment. See our full analysis for Lemonade. Next up, we will see how...

Hinge Health (HNGE) is expected to see revenue grow at 13.6% per year, outpacing the broader US market’s 10.5% forecast. While the company is not yet profitable, earnings are projected to surge at an annual rate of 92.55%, with profitability likely within the next three years. Despite a lack of long-term trading history and recent share price volatility, investors may focus on the high growth potential as a key positive for Hinge Health. See our full analysis for Hinge Health. Next, we will...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Montrose Environmental Group (MEG) is forecasting revenue growth of 5.5% per year, trailing the wider US market’s expected 10.5% pace. The company remains in the red, but it has trimmed annual losses by an average of 11.1% over the past five years. While profitability remains elusive, investors are weighing the steady narrowing of losses against slower sales expansion and a premium Price-To-Sales Ratio. See our full analysis for Montrose Environmental Group. Now, let’s see how these latest...

Accel Entertainment (ACEL) reported a net profit margin of 2.8%, down from last year’s 4.1%. Despite achieving an impressive annualized earnings growth rate of 28.9% over the last five years, earnings turned negative in the most recent year, halting positive profit momentum. With revenue projected to grow at 3.8% per year and a price-to-earnings ratio of 24.3x, which is above the US Hospitality industry average, the numbers paint a more cautious outlook, especially given the stock trades...

Jack Henry & Associates (JKHY) posted a 19.4% jump in earnings over the last year, far above its 7.5% average annual growth for the past five years. Net profit margins improved to 19.2%, compared to 17.2% a year earlier, highlighting a run of high-quality results. Though revenue and earnings are each expected to keep growing, future rates of 6.4% and 8.2% per year, respectively, trail behind broader US market forecasts. Despite a premium valuation compared to peers and the industry, strong...

California Resources (CRC) posted eye-catching results this quarter, with net profit margins jumping to 18.3%, up from 7.2% a year ago. Earnings rebounded 305.5% year-over-year, a major turnaround from the company’s five-year average decline of -25.6% annually. The share price sits at $46.27, well below an analyst fair value estimate of $114.76. This signals that investors are weighing strong profitability against looming concerns over slower revenue growth and projected earnings...

Curious whether Royalty Pharma is trading at a bargain, or if its recent performance signals something more? You are not alone. Valuation-focused investors have been eyeing this stock closely. After a strong run, Royalty Pharma’s shares are up 10.2% in the last week and 11.9% this month, racking up an impressive 56.7% gain year-to-date. Recent headlines have highlighted Royalty Pharma's aggressive moves in acquiring new royalty interests and expanding its biopharma portfolio. Both of these...

Wondering if uniQure’s rollercoaster stock price means it’s a bargain or a trap? Let’s dig into what’s really driving its value. uniQure shares have seen wild swings lately, dropping 63.1% in just the past week, but are still up an eye-catching 264.0% over the last year. This highlights both volatility and dramatic growth potential. Much of this action has been fueled by recent headlines about regulatory milestones for its gene therapy pipeline and an announced partnership set to expand its...

Wondering if Fresenius SE KGaA is truly a bargain or just riding the wave? You're not alone. The stock's value is a hot topic for investors eyeing healthcare giants. After soaring 43.5% year-to-date, with a 41.7% gain over the last year, it's clear things are moving. However, the past week has seen a 5.0% pullback, adding a dose of short-term volatility to the mix. Recent headlines have revolved around Fresenius advancing its strategic transformation, including portfolio streamlining and a...

Stella-Jones (TSX:SJ) is forecast to grow earnings at 1% per year, trailing behind the broader Canadian market’s 12.1% rate, while revenue is expected to increase by 5.6% annually, outpacing the market’s 5.1%. The company currently reports net profit margins of 9.6%, slightly lower than last year’s 10.2%, but has averaged 11.1% annual earnings growth over the past five years. Investors may take comfort in the high quality of these earnings, with shares trading at a PE ratio of 13.8 times,...

ACM Research (ACMR) is on track for robust growth, with revenue forecast to climb 15% per year, well ahead of the broader US market’s 10.5% annual growth. EPS is set to expand by 14.3% annually, net profit margins have increased to 13.8% from 12.3% last year, and earnings have averaged a 37% annual increase over the past five years. Investors may take notice as strong margin improvement and premium revenue growth continue to support a positive outlook, even as recent share price stability...

United Fire Group (UFCS) delivered eye-catching results this year, with earnings surging 149.9% from a year ago and outpacing its own five-year annual earnings growth rate of 40.1%. Net profit margins rose to 6.9%, up from last year’s 3.2%. This reflects a solid uptrend in profitability while the company continues to grow earnings at a strong compounded annual pace. Investors now face the prospects of continued growth, high-quality earnings, and improved margins, balanced against valuation...

Niagen Bioscience (NAGE) posted annual revenue growth of 17.4%, beating the US market’s 10.5% pace. The bottom line also showed a significant turnaround, as the company turned profitable in the last year with a notable improvement in net profit margin. Earnings are now expected to grow at a rapid 41.2% per year over the next three years, compared to the broader market’s 16% growth estimate. Shares currently trade at $6.88, which is well below management’s internal fair value mark of $18.44...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

The Middle Eastern stock markets have recently experienced a downturn, with most Gulf bourses tracking global shares lower due to concerns over high valuations. Despite this challenging environment, dividend stocks can offer stability and income potential for investors seeking resilience during market fluctuations.